SAVOR-TIMI 53 was a randomized, double-blind, placebo-controlled trial to assess the cardiovascular efficacy and safety of saxagliptin, a DPP-4 inhibitor, when added to standard of care in patients with type 2 diabetes mellitus. MAIN RESULTS:Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusN Engl J Med. 2013 Oct 3;369(14):1317-26. PRESENTATIONS TIMI 53 SlidesHF … Continue reading SAVOR-TIMI 53